HERON THERAPEUTICS INC (HRTX)

US4277461020 - Common Stock

1.06  -0.06 (-5.36%)

After market: 1.09 +0.03 (+2.83%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

HERON THERAPEUTICS INC

NASDAQ:HRTX (11/21/2024, 8:00:01 PM)

After market: 1.09 +0.03 (+2.83%)

1.06

-0.06 (-5.36%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-69.19%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap161.22M
Shares
PEN/A
Fwd PE446.02
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

HRTX Daily chart

Company Profile

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. The company is headquartered in San Diego, California and currently employs 126 full-time employees. The firm commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.

Company Info

HERON THERAPEUTICS INC

4242 Campus Point Court, Suite 200

San Diego CALIFORNIA 92121

P: 18582514400

CEO: Barry Quart

Employees: 126

Website: https://www.herontx.com/

HRTX News

ChartMill News Image9 days ago - ChartmillHere are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.

ChartMill News Image10 days ago - ChartmillWhich stocks are gapping on Tuesday?

The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.

News Image10 days ago - Heron Therapeutics, Inc.Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results...

News Image17 days ago - Heron Therapeutics, Inc.Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its...

News Image23 days ago - Heron Therapeutics, Inc.Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company...

News Imagea month ago - Heron Therapeutics, Inc.Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTIĀ®, SUSTOLĀ®, and APONVIEĀ® as Alternatives During the Potential Shortage of Intravenous Fluids

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's...

HRTX Twits

Here you can normally see the latest stock twits on HRTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example